Skip to main content

12-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Researcher comment: Phase IIb study of fenebrutinib in RA patients

Lead investigator Stanley Cohen discusses the key results for the multi-dose trial of fenebrutinib versus placebo and adalimumab in patients with rheumatoid arthritis refractory to methotrexate or prior tumor necrosis factor inhibitor therapy (2:05).

Related topics